Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells

International Journal of Clinical Oncology

Volumn 16, Issue 6, 2011, Pages 671-678

  Iwahashi, Shuichi ^a   Shimada, Mitsuo ^a   Utsunomiya, Tohru ^a   Morine, Yuji ^a   Imura, Satoru ^a   Ikemoto, Tetsuya ^a   Mori, Hiroki ^a   Hanaoka, Jun ^a   Sugimoto, Koji ^a   Saito, Yu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Gemcitabine; HDAC inhibitor; Pancreas cancer; Pegylated interferon ; Valproic acid

Indexed keywords

GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; HIF 1 GENE; HISTONE DEACETYLASE 1 GENE; HUMAN; HUMAN CELL; MTA1 GENE; P21 WAF1 GENE; PANCREAS CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYCYTIDINE; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERFERON-ALPHA; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; VALPROIC ACID;

EID: 84855195742     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0246-y     Document Type: Article

References (47)

1. M Hidalgo 2010 Pancreatic cancer N Engl J Med 362 1605 1617 20427809 10.1056/NEJMra0901557 1:CAS:528:DC%2BC3cXlsV2ns7o%3D
2. HA Burris III MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
3. M Haberland RL Montgomery EN Olson 2009 The many roles of histone deacetylases in development and physiology: implications for disease and therapy Nat Rev Genet 10 32 42 19065135 10.1038/nrg2485 1:CAS:528:DC%2BD1cXhsFWis7bI
4. S Minucci PG Pelicci 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 38 51 16397526 10.1038/nrc1779 1:CAS:528:DC%2BD28Xht1GgsA%3D%3D (Pubitemid 43054973)
5. MA Glozak E Seto 2007 Histone deacetylases and cancer Oncogene 26 5420 5432 17694083 10.1038/sj.onc.1210610 1:CAS:528:DC%2BD2sXovFeku7Y%3D (Pubitemid 47255924)
6. SK Patra A Patra R Dahiya 2001 Histone deacetylase and DNA methyltransferase in human prostate cancer Biochem Biophys Res Commun 287 705 713 11563853 10.1006/bbrc.2001.5639 1:CAS:528:DC%2BD3MXmvV2jsb4%3D (Pubitemid 32912772)
7. P Zhu E Martin J Mengwasser, et al. 2004 Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis Cancer Cell 5 455 463 15144953 10.1016/S1535-6108(04)00114-X 1:CAS:528:DC%2BD2cXksFCmt7c%3D (Pubitemid 38610247)
8. RJ Lin L Nagy S Inoue, et al. 1998 Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 391 811 814 9486654 10.1038/35895 1:CAS:528:DyaK1cXhtlCisr4%3D (Pubitemid 28099682)
9. K Miyake T Yoshizumi S Imura, et al. 2008 Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation Pancreas 36 e1 e9 18362831 10.1097/MPA.0b013e31815f2c2a 1:CAS:528: DC%2BD1cXkvVenur0%3D (Pubitemid 351440946)
10. JE Bolden MJ Peart RW Johnstone 2005 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 769 784 10.1038/nrd2133
11. RP Warrell Jr LZ He V Richon, et al. 1998 Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J Natl Cancer Inst 90 1621 1625 9811311 10.1093/jnci/90.21.1621 1:CAS:528:DyaK1cXnsVCgt7k%3D (Pubitemid 28523436)
12. M Göttlicher S Minucci P Zhu, et al. 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 6969 6978 11742974 10.1093/emboj/20.24.6969 (Pubitemid 34062289)
13. Q Xia J Sung W Chowdhury, et al. 2006 Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo Cancer Res 66 7237 7244 16849572 10.1158/0008-5472.CAN-05-0487 1:CAS:528:DC%2BD28XmvFGktbw%3D (Pubitemid 44197704)
14. MG Catalano N Fortunati M Pugliese, et al. 2005 Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells J Clin Endocrinol Metab 90 1383 1389 15585556 10.1210/jc.2004-1355 1:CAS:528:DC%2BD2MXisVOhs7k%3D (Pubitemid 40463993)
15. S Baron F Dianzani 1994 The interferons: a biological system with therapeutic potential in viral infections Antiviral Res 24 97 110 7526796 10.1016/0166-3542(94)90058-2 1:CAS:528:DyaK2cXltlWksL4%3D (Pubitemid 24228865)
16. PJ Hertzog SY Hwang I Kola 1994 Role of interferons in the regulation of cell proliferation, differentiation and development Mol Reprod Dev 39 226 232 7530016 10.1002/mrd.1080390216 1:CAS:528:DyaK2cXmsFeit74%3D (Pubitemid 24312166)
17. JU Gutterman 1994 Cytokine therapeutics: lessons from interferon-α Proc Natl Acad Sci USA 91 1198 1205 8108387 10.1073/pnas.91.4.1198 1:CAS:528:DyaK2cXhvV2js70%3D
18. SE Krown 1988 Interferons in malignancy: biological products or biological response modifiers? J Natl Cancer Inst (Bethesda) 80 306 309 10.1093/jnci/80.5.306 1:STN:280:DyaL1c7ovVajtQ%3D%3D
19. K Miyake K Tsuchida H Sugino, et al. 2007 Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha Cancer Chemother Pharmacol 59 113 126 16699793 10.1007/s00280-006-0250-5 1:CAS:528:DC%2BD28Xht1entLzO (Pubitemid 44796109)
20. DE Baker 2003 Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C Rev Gastroenterol Disord 3 93 109 12776006 (Pubitemid 36701289)
21. T Yamada K Furukawa K Yokoi, et al. 2010 Effects of irinotecan and 5-FU combination therapy in gastric cancer-is combination therapy synergic (in Japanese)? Gan To Kagaku Ryoho 37 2125 2129 21084811
22. YG Yoo G Kong MO Lee 2006 Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1 EMBO J 25 1231 1241 16511565 10.1038/sj.emboj.7601025 1:CAS:528:DC%2BD28Xis1Gku7k%3D
23. WK Kelly OA O'Connor LM Krug, et al. 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 3923 3931 15897550 10.1200/JCO.2005.14.167 1:CAS:528:DC%2BD2MXmtVahtLw%3D (Pubitemid 46218695)
24. L Fuino P Bali S Wittmann, et al. 2003 Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 971 984 14578462 1:CAS:528:DC%2BD3sXosVCqt7g%3D
25. BK Rundall CE Denlinger DR Jones 2005 Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer Surgery 138 360 367 16153448 10.1016/j.surg.2005.06.016 (Pubitemid 41253822)
26. WS El-Deiry T Tokino VE Velculescu, et al. 1993 WAF1, a potential mediator of p53 tumor suppression Cell 75 817 825 8242752 10.1016/0092-8674(93) 90500-P 1:CAS:528:DyaK2cXpslGguw%3D%3D (Pubitemid 23346378)
27. WS El-Deiry JW Harper PM O'Connor, et al. 1994 WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis Cancer Res 54 1169 1174 8118801 1:CAS:528:DyaK2cXivFCkuro%3D (Pubitemid 24108052)
28. C Deng P Zhang JW Harper, et al. 1995 Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control Cell 82 675 684 7664346 10.1016/0092-8674(95)90039-X 1:CAS:528:DyaK2MXnvVWmtbo%3D
29. J Schwaller HP Koeffler G Niklaus, et al. 1995 Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells J Clin Invest 95 973 979 7883998 10.1172/JCI117806 1:CAS:528:DyaK2MXktlKht7s%3D
30. JA DiGiuseppe MS Redston CJ Yeo, et al. 1995 p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma Am J Pathol 147 884 888 7573363 1:STN:280:DyaK28%2FhtVamsQ%3D%3D
31. L Huang Y Sowa T Sakai, et al. 2000 Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites Oncogene 19 5712 5719 11126357 10.1038/sj.onc.1203963 1:CAS:528:DC%2BD3cXoslylsLs%3D
32. CM Das D Aguilera H Vasquez, et al. 2007 Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines J Neurooncol 85 159 170 17534580 10.1007/s11060-007-9402-7 1:CAS:528:DC%2BD2sXhtl2gs73O (Pubitemid 47629397)
33. M Donadelli C Costanzo L Faggioli, et al. 2003 Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells Mol Carcinog 38 59 69 14502645 10.1002/mc.10145 1:CAS:528:DC%2BD3sXotlWiur4%3D (Pubitemid 37255141)
34. VM Richon TW Sandhoff RA Rifkind, et al. 2000 Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc Natl Acad Sci USA 97 10014 10019 10954755 10.1073/pnas. 180316197 1:CAS:528:DC%2BD3cXmtlehsL4%3D
35. B Nichole A Nohea G Jason, et al. 2007 The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer Clin Cancer Res 13 18 26 10.1158/1078-0432.CCR-06-0914 (Pubitemid 46121848)
36. P Tagliaferri M Caraglia A Budillon, et al. 2005 New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer Cancer Immunol Immunother 54 1 10 15693134 10.1007/s00262-004-0549-1 1:CAS:528:DC%2BD2cXhtVWjt7%2FN (Pubitemid 40064480)
37. Y Toh SD Pencil GL Nicolson 1994 A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses J Biol Chem 269 22958 22963 8083195 1:CAS:528:DyaK2MXnsF2ntw%3D%3D
38. R Kumar 2003 Another tie that binds the MTA family to breast cancer Cell 113 142 143 12705862 10.1016/S0092-8674(03)00274-5 1:CAS:528: DC%2BD3sXjtlOqs7o%3D (Pubitemid 36514965)
39. NJ Bowen N Fujita M Kajita, et al. 2004 Mi-2/NuRD: multiple complexes for many purposes Biochim Biophys Acta 1677 52 57 15020045 1:CAS:528: DC%2BD2cXitFejsrk%3D (Pubitemid 38327088)
40. VJ Picozzi RA Kozarek LW Traverso 2003 Interferon based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg 185 4767 4780 10.1016/S0002-9610(03)00051-5 (Pubitemid 36513960)
41. CC Solorzano R Hwang CH Baker, et al. 2003 Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice Clin Cancer Res 9 1858 1867 12738744 1:CAS:528:DC%2BD3sXjsFeitLk%3D (Pubitemid 36554614)
42. F Perez-Zincer T Olencki GT Budd, et al. 2002 A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma Invest New Drugs 20 305 310 12211213 10.1023/A:1016214030069 1:CAS:528:DC%2BD38XltFans7s%3D (Pubitemid 34823758)
43. S Fuxius K Mross K Mansouri, et al. 2002 Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer Anticancer Drugs 13 899 905 12394252 10.1097/00001813-200210000-00001 1:CAS:528:DC%2BD38XotVCmtLY%3D (Pubitemid 35388191)
44. RJ Amato M Khan 2008 A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma Cancer Chemother Pharmacol 61 1069 1073 17701037 10.1007/s00280-007-0568-7 1:CAS:528:DC%2BD1cXjsF2gs70%3D (Pubitemid 351423135)
45. C Krepler U Certa V Wacheck, et al. 2004 Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model J Invest Dermatol 123 664 669 15373770 10.1111/j.0022-202X.2004.23433.x 1:CAS:528:DC%2BD2cXot1Kgs74%3D (Pubitemid 39281606)
46. RA Blaheta M Michaelis PH Driever, et al. 2005 Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies Med Res Rev 25 383 397 15637697 10.1002/med.20027 1:CAS:528:DC%2BD2MXntlSktbg%3D (Pubitemid 40946533)
47. A Faiella M Wernig GG Consalez, et al. 2000 A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression Hum Mol Genet 9 227 236 10607833 10.1093/hmg/9.2.227 1:CAS:528:DC%2BD3cXhtVaksL8%3D (Pubitemid 30052746)